T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple-Negative Breast Cancer
Interventions: DRUG: Trastuzumab Deruxtecan
Sponsor: Fudan University